The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 10, 2016, Pages 4144-4150

  Rezar Dreindl, Sandra ^a   Sacu, Stefan ^a   Eibenberger, Katharina ^a   Pollreisz, Andreas ^a   Bühl, Wolf ^a   Georgopoulos, Michael ^a   Krall, Christoph ^a   Weigert, Günther ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti vascular endothelial growth factor; Cytokines; Dexamethasone intravitreal implant; Neovascular age related macular degeneration

Indexed keywords

DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GELATINASE B; GENTAMICIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; RANIBIZUMAB; SCATTER FACTOR; SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE PROTEIN; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CYTOKINE; DRUG IMPLANT; GLUCOCORTICOID;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VISUAL ACUITY; AQUEOUS HUMOR; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG IMPLANT; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; METABOLISM; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINAL NEOVASCULARIZATION; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; AQUEOUS HUMOR; CYTOKINES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINAL NEOVASCULARIZATION; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84983048315     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-19772     Document Type: Article

References (35)

1. Campa C, Costagliola C, Incorvaia C, et al. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010;2010:546-826.
2. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331-371.
3. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999;3:34.
4. Fauser S, Viebahn U, Muether PS. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2015;93:734-738.
5. Agawa T, Usui Y, Wakabayashi Y, et al. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Retina. 2014;34:1811-1818.
6. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
7. Funk M, Karl D, Georgopoulos M, et al. Neovascular agerelated macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009;116:2393-2399.
8. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19: 361-372.
9. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175-1183.
10. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2006;15:779-793.
11. Rofagha S, Bhisitkul RB, Boyer DS, et al; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-2299.
12. Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatmentresistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92:713-723.
13. Kuppermann BD, Goldstein M, Maturi RK, et al. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. Ophthalmologica. 2015;234:40-54.
14. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative agerelated macular degeneration. Arch Ophthalmol. 2004;122: 218-222.
15. Lim JI, Niec M, Wong V. One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Br J Ophthalmol. 2015;99:618-623.
16. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
17. Rayess N, Houston SK, Gupta OP, Ho AC, Regillo CD. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol. 2015;159:3-8.
18. Yu SY, Damico FM, Viola F, D’Amico DJ, Young LH. Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina. 2006;26:531-536.
19. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259-266.
20. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011; 118:2453-2460.
21. Cao JH, Mulvahill M, Zhang L, Joondeph BC, Dacey MS. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology. 2014;121:1871-1876.
22. Scaramuzzi M, Querques G, Spina C, Lattanzio R, Bandello F. Repeated invtravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina. 2015;35:1216-1222.
23. Shure D, Senior RM, Griffin GL, Deuel TF. PDGF AA homodimers are potent chemoattractants for fibroblasts and neutrophils, and for monocytes activated by lymphocytes or cytokines. Biochem Biophys Res Commun. 1992;14:1510-1514.
24. Kliffen M, Sharmab HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol. 1997;81:154-162.
25. Shikada Y, Yonemitsu Y, Koga T, et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res. 2005;15:7241-7248.
26. Naucka M, Karakiulakis G, Perruchoudc AP, Papakonstantinoub E, Rothc M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
27. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246:1309-1315.
28. Ogata N, Yamamoto C, Miyashiro M, Yamada H, Matsushima M, Uyama M. Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization. Curr Eye Res. 1997;16:9-18.
29. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-b2 in human retinal pigment epithelial cells. Exp Eye Res. 2007;84:812-822.
30. Zarranz-Ventura J, Fernández-Robredo P, Recalde S, et al. Transforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides. PLoS One. 2013;31;8.
31. Potchinsky M, Nugent P, Lafferty C, Greene RM. Effects of dexamethasone on the expression of transforming growth factor-beta in mouse embryonic palatal mesenchymal cells. J Cell Physiol. 1996;166:380-386.
32. Jonas JB, Tao Y, Neumaier M, Findeisen P. Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch Ophthalmol. 2010;128:1281-1286.
33. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997;61:246-257.
34. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epitheliumderived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141: 456-462.
35. Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Retina. 2009;29:523-529.